BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med. 2019;381:1632-1643. [PMID: 31566309 DOI: 10.1056/nejmoa1908075] [Cited by in Crossref: 353] [Cited by in F6Publishing: 178] [Article Influence: 117.7] [Reference Citation Analysis]
Number Citing Articles
1 Cheng WL, Feng PH, Lee KY, Chen KY, Sun WL, Van Hiep N, Luo CS, Wu SM. The Role of EREG/EGFR Pathway in Tumor Progression. Int J Mol Sci 2021;22:12828. [PMID: 34884633 DOI: 10.3390/ijms222312828] [Reference Citation Analysis]
2 Kratz JD, Deming DA. The evolving treatment paradigm for BRAF V600 mutant colorectal cancer. Ann Transl Med 2019;7:S257. [PMID: 32015976 DOI: 10.21037/atm.2019.12.61] [Reference Citation Analysis]
3 Bang YH, Kim JE, Lee JS, Kim SY, Kim KP, Kim TW, Hong YS. Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Sci Rep 2021;11:7118. [PMID: 33782470 DOI: 10.1038/s41598-021-86482-x] [Reference Citation Analysis]
4 Cohen R, Pudlarz T, Delattre JF, Colle R, André T. Molecular Targets for the Treatment of Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E2350. [PMID: 32825275 DOI: 10.3390/cancers12092350] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Taniguchi H, Uehara K, Nakayama G, Nakayama H, Aiba T, Hattori N, Kataoka M, Nakano Y, Kawase Y, Okochi O, Matsuoka H, Utsunomiya S, Sakamoto E, Mori Y, Umeda S, Shikano T, Komori K, Tajika M, Kadowaki S, Muro K, Yatabe Y. Tumor Location Is Associated With the Prevalence of Braf And Pik3ca Mutations in Patients with Wild-Type Ras Colorectal Cancer: A Prospective Multi-Center Cohort Study in Japan. Transl Oncol 2020;13:100786. [PMID: 32428838 DOI: 10.1016/j.tranon.2020.100786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Niogret J, Limagne E, Thibaudin M, Blanc J, Bertaut A, Le Malicot K, Rinaldi Y, Caroli-Bosc FX, Audemar F, Nguyen S, Sarda C, Lombard-Bohas C, Locher C, Carreiro M, Legoux JL, Etienne PL, Baconnier M, Porneuf M, Aparicio T, Ghiringhelli F. Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma. Cancers (Basel) 2020;12:E1429. [PMID: 32486421 DOI: 10.3390/cancers12061429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Hinoi T. Cancer Genomic Profiling in Colorectal Cancer: Current Challenges in Subtyping Colorectal Cancers Based on Somatic and Germline Variants. J Anus Rectum Colon 2021;5:213-28. [PMID: 34395933 DOI: 10.23922/jarc.2021-009] [Reference Citation Analysis]
8 Gallois C, Taieb J, Sabouret A, Broudin C, Karoui M, Garinet S, Zaanan A. Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report. Genes Chromosomes Cancer 2022;61:114-8. [PMID: 34773327 DOI: 10.1002/gcc.23012] [Reference Citation Analysis]
9 Aparicio J, Esposito F, Serrano S, Falco E, Escudero P, Ruiz-Casado A, Manzano H, Fernandez-Montes A. Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease. J Clin Med 2020;9:E3889. [PMID: 33265959 DOI: 10.3390/jcm9123889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Di Nicolantonio F, Vitiello PP, Marsoni S, Siena S, Tabernero J, Trusolino L, Bernards R, Bardelli A. Precision oncology in metastatic colorectal cancer - from biology to medicine. Nat Rev Clin Oncol 2021;18:506-25. [PMID: 33864051 DOI: 10.1038/s41571-021-00495-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Hendifar A, Blais EM, Wolpin B, Subbiah V, Collisson E, Singh I, Cannon T, Shaw K, Petricoin EF 3rd, Klempner S, Lyons E, Wang-Gillam A, Pishvaian MJ, O'Reilly EM. Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. JCO Precis Oncol 2021;5:PO. [PMID: 34476331 DOI: 10.1200/PO.20.00494] [Reference Citation Analysis]
12 Molina-Cerrillo J, San Román M, Pozas J, Alonso-Gordoa T, Pozas M, Conde E, Rosas M, Grande E, García-Bermejo ML, Carrato A. BRAF Mutated Colorectal Cancer: New Treatment Approaches. Cancers (Basel) 2020;12:E1571. [PMID: 32545884 DOI: 10.3390/cancers12061571] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
13 Patelli G, Vaghi C, Tosi F, Mauri G, Amatu A, Massihnia D, Ghezzi S, Bonazzina E, Bencardino K, Cerea G, Siena S, Sartore-Bianchi A. Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA. Target Oncol 2021;16:309-24. [PMID: 33738696 DOI: 10.1007/s11523-021-00795-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Siu HWD, Tebbutt N, Chantrill L, Karapetis C, Steer C, Wilson K, Espinoza D, Bailey L, Yip S, Cuff J, Pavlakis N, Thavaneswaran S, Briscoe K, Srivastav R, Shannon J, Segelov E, Tie J, Caird S, Francesconi A, Price T, Wuttke M, Ladwa R, Sjoquist K, Burge M. MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). BMC Cancer 2021;21:932. [PMID: 34407800 DOI: 10.1186/s12885-021-08644-4] [Reference Citation Analysis]
15 Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. Genes Dev 2021;35:787-820. [PMID: 34074695 DOI: 10.1101/gad.348226.120] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Cen S, Liu K, Zheng Y, Shan J, Jing C, Gao J, Pan H, Bai Z, Liu Z. BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer. Front Cell Dev Biol 2021;9:705060. [PMID: 34381786 DOI: 10.3389/fcell.2021.705060] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Bai Y, Sha J, Okui T, Moriyama I, Ngo HX, Tatsumi H, Kanno T. The Epithelial-Mesenchymal Transition Influences the Resistance of Oral Squamous Cell Carcinoma to Monoclonal Antibodies via Its Effect on Energy Homeostasis and the Tumor Microenvironment. Cancers (Basel) 2021;13:5905. [PMID: 34885013 DOI: 10.3390/cancers13235905] [Reference Citation Analysis]
18 Huijberts SCFA, Boelens MC, Bernards R, Opdam FL. Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib. Br J Cancer 2021;124:176-82. [PMID: 33204026 DOI: 10.1038/s41416-020-01147-2] [Reference Citation Analysis]
19 De Conti G, Dias MH, Bernards R. Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells. Cancers (Basel) 2021;13:1118. [PMID: 33807785 DOI: 10.3390/cancers13051118] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Lai E, Cascinu S, Scartozzi M. Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. Front Oncol 2021;11:637823. [PMID: 34041019 DOI: 10.3389/fonc.2021.637823] [Reference Citation Analysis]
21 Kholodenko BN, Rauch N, Kolch W, Rukhlenko OS. A systematic analysis of signaling reactivation and drug resistance. Cell Rep 2021;35:109157. [PMID: 34038718 DOI: 10.1016/j.celrep.2021.109157] [Reference Citation Analysis]
22 Song X, Xie D, Tan F, Zhou Y, Li Y, Zhou Z, Pei Q, Pei H. Intravascular emboli relates to immunosuppressive tumor microenvironment and predicts prognosis in stage III colorectal cancer. Aging (Albany NY) 2021;13:20609-28. [PMID: 34438367 DOI: 10.18632/aging.203451] [Reference Citation Analysis]
23 Eurboonyanun K, Lahoud RM, Kordbacheh H, Pourvaziri A, Promsorn J, Chadbunchachai P, O'Shea A, Atre ID, Harisinghani M. Imaging predictors of BRAF mutation in colorectal cancer. Abdom Radiol (NY) 2020;45:2336-44. [PMID: 32193591 DOI: 10.1007/s00261-020-02484-9] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Butt SU, Mejias A, Morelli C, Torga G, Happe M, Patrikidou A, Arkenau HT. BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series. Cancer Chemother Pharmacol 2021;87:437-41. [PMID: 33537843 DOI: 10.1007/s00280-021-04234-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Owsley J, Stein MK, Porter J, In GK, Salem M, O'Day S, Elliott A, Poorman K, Gibney G, VanderWalde A. Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database. Exp Biol Med (Maywood) 2021;246:31-9. [PMID: 33019809 DOI: 10.1177/1535370220959657] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kastrisiou M, Zarkavelis G, Kougioumtzi A, Sakaloglou P, Kostoulas C, Georgiou I, Batistatou A, Pentheroudakis G, Magklara A. Development and Validation of a Targeted ‘Liquid’ NGS Panel for Treatment Customization in Patients with Metastatic Colorectal Cancer. Diagnostics 2021;11:2375. [DOI: 10.3390/diagnostics11122375] [Reference Citation Analysis]
27 Tabbò F, Pisano C, Mazieres J, Mezquita L, Nadal E, Planchard D, Pradines A, Santamaria D, Swalduz A, Ambrogio C, Novello S, Ortiz-cuaran S. How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). Cancer Treatment Reviews 2022;103:102335. [DOI: 10.1016/j.ctrv.2021.102335] [Reference Citation Analysis]
28 Lee Y, Lee S, Sung JS, Chung HJ, Lim AR, Kim JW, Choi YJ, Park KH, Kim YH. Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project. Cancer Res Treat 2021;53:123-30. [PMID: 32810930 DOI: 10.4143/crt.2020.559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB 3rd, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020;17:757-770. [PMID: 32632268 DOI: 10.1038/s41571-020-0392-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 19.5] [Reference Citation Analysis]
30 Athauda A, Fong C, Lau DK, Javle M, Abou-Alfa GK, Morizane C, Steward K, Chau I. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. Cancer Treat Rev 2020;86:101998. [PMID: 32203843 DOI: 10.1016/j.ctrv.2020.101998] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
31 Pfeiffer P, Qvortrup C. KRASG12C inhibition in colorectal cancer. Lancet Oncol 2022;23:10-1. [PMID: 34919826 DOI: 10.1016/S1470-2045(21)00652-5] [Reference Citation Analysis]
32 Li QH, Wang YZ, Tu J, Liu CW, Yuan YJ, Lin R, He WL, Cai SR, He YL, Ye JN. Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. Gastroenterol Rep (Oxf) 2020;8:179-91. [PMID: 32665850 DOI: 10.1093/gastro/goaa026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
33 Kanat O, Ertas H, Caner B. Contemporary treatment approaches for metastatic colorectal cancer driven by BRAF V600 mutations. World J Gastrointest Oncol 2020; 12(10): 1080-1090 [PMID: 33133378 DOI: 10.4251/wjgo.v12.i10.1080] [Reference Citation Analysis]
34 Wookey V, Grothey A. Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer. Therap Adv Gastroenterol 2021;14:17562848211024460. [PMID: 34262612 DOI: 10.1177/17562848211024460] [Reference Citation Analysis]
35 Narasimhan V, Wright JA, Churchill M, Wang T, Rosati R, Lannagan TRM, Vrbanac L, Richardson AB, Kobayashi H, Price T, Tye GXY, Marker J, Hewett PJ, Flood MP, Pereira S, Whitney GA, Michael M, Tie J, Mukherjee S, Grandori C, Heriot AG, Worthley DL, Ramsay RG, Woods SL. Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy. Clin Cancer Res 2020;26:3662-70. [PMID: 32376656 DOI: 10.1158/1078-0432.CCR-20-0073] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 10.5] [Reference Citation Analysis]
36 Das S, Berlin J. Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases. Surg Oncol Clin N Am 2021;30:189-204. [PMID: 33220805 DOI: 10.1016/j.soc.2020.08.008] [Reference Citation Analysis]
37 Aleksakhina SN, Imyanitov EN. Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives. Int J Mol Sci 2021;22:10931. [PMID: 34681592 DOI: 10.3390/ijms222010931] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Hon KW, Zainal Abidin SA, Othman I, Naidu R. The Crosstalk Between Signaling Pathways and Cancer Metabolism in Colorectal Cancer. Front Pharmacol 2021;12:768861. [PMID: 34887764 DOI: 10.3389/fphar.2021.768861] [Reference Citation Analysis]
39 Alawawdeh A, Price T, Karapetis C, Piantadosi C, Padbury R, Roy A, Maddern G, Moore J, Carruthers S, Roder D, Townsend AR. Regorafenib outcomes from the population based South Australian Metastatic Colorectal Cancer Registry. Asia Pac J Clin Oncol 2021. [PMID: 34811937 DOI: 10.1111/ajco.13672] [Reference Citation Analysis]
40 Huynh JC, Schwab E, Ji J, Kim E, Joseph A, Hendifar A, Cho M, Gong J. Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies. Cancers (Basel). 2020;12. [PMID: 32384640 DOI: 10.3390/cancers12051168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
41 Mata DA, Yang SR, Ferguson DC, Liu Y, Sharma R, Benhamida JK, Al-Ahmadie HA, Chakravarty D, Solit DB, Tickoo SK, Gupta S, Arcila ME, Ladanyi M, Feldman DR, Reuter VE, Vanderbilt CM. RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors. Urology 2020;144:111-6. [PMID: 32721511 DOI: 10.1016/j.urology.2020.07.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Chen HH, Ke TW, Huang CW, Jiang JK, Chen CC, Hsieh YY, Teng HW, Lin BW, Liang YH, Su YL, Hsu HC, Kuan FC, Chou YH, Lin J, Lin BR, Chang YY, Wang JY. Taiwan Society of Colon and Rectal Surgeons Consensus on mCRC Treatment. Front Oncol 2021;11:764912. [PMID: 34868987 DOI: 10.3389/fonc.2021.764912] [Reference Citation Analysis]
43 Lau DK, Mencel J, Chau I. Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer. Expert Opin Drug Saf 2022;:1-9. [PMID: 34986714 DOI: 10.1080/14740338.2022.2008905] [Reference Citation Analysis]
44 Grassi E, Corbelli J, Papiani G, Barbera MA, Gazzaneo F, Tamberi S. Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer. Front Oncol 2021;11:601722. [PMID: 34249672 DOI: 10.3389/fonc.2021.601722] [Reference Citation Analysis]
45 Schneider G, Wirth M, Keller U, Saur D. Rationale for MYC imaging and targeting in pancreatic cancer. EJNMMI Res 2021;11:104. [PMID: 34637026 DOI: 10.1186/s13550-021-00843-1] [Reference Citation Analysis]
46 Kobayashi S, Takahashi S, Yoshino T, Taniguchi H. ASO Author Reflections: The Moment That BRAF V600E Mutation Starts Evolving into "Precision Oncosurgery" in Colorectal Liver Metastases. Ann Surg Oncol 2020;27:3316-7. [PMID: 32642996 DOI: 10.1245/s10434-020-08818-7] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Janssen E, Subtil B, de la Jara Ortiz F, Verheul HMW, Tauriello DVF. Combinatorial Immunotherapies for Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E1875. [PMID: 32664619 DOI: 10.3390/cancers12071875] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
48 Wong V, Lee M, Wong R, Tie J, Shapiro J, Desai J, Nott L, Steel S, Burge M, Ma B, Khattak A, Hong W, Gibbs P. BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset? Target Oncol 2021;16:227-36. [PMID: 33599905 DOI: 10.1007/s11523-021-00793-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Hiraide S, Takahashi M, Yoshida Y, Yamada H, Komine K, Ishioka C. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer. Cancer Sci 2021;112:3856-70. [PMID: 34288281 DOI: 10.1111/cas.15075] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Giampieri R, Cantini L, Giglio E, Bittoni A, Lanese A, Crocetti S, Pecci F, Copparoni C, Meletani T, Lenci E, Lupi A, Baleani MG, Berardi R. Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing. Cancers (Basel) 2020;12:E2724. [PMID: 32977434 DOI: 10.3390/cancers12102724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Wang J, Li R, Li J, Yi Y, Liu X, Chen J, Zhang H, Lu J, Li C, Wu H, Liang Z. Comprehensive analysis of oncogenic fusions in mismatch repair deficient colorectal carcinomas by sequential DNA and RNA next generation sequencing. J Transl Med 2021;19:433. [PMID: 34657620 DOI: 10.1186/s12967-021-03108-6] [Reference Citation Analysis]
52 Bitzer M, Ostermann L, Horger M, Biskup S, Schulze M, Ruhm K, Hilke F, Öner Ö, Nikolaou K, Schroeder C, Riess O, Fend F, Zips D, Hinterleitner M, Zender L, Tabatabai G, Beha J, Malek NP. Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options. JCO Precis Oncol 2020;4:PO. [PMID: 32923905 DOI: 10.1200/PO.19.00359] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
53 Ponsioen B, Post JB, Buissant des Amorie JR, Laskaris D, van Ineveld RL, Kersten S, Bertotti A, Sassi F, Sipieter F, Cappe B, Mertens S, Verlaan-Klink I, Boj SF, Vries RGJ, Rehmann H, Vandenabeele P, Riquet FB, Trusolino L, Bos JL, Snippert HJG. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling. Nat Cell Biol 2021;23:377-90. [PMID: 33795873 DOI: 10.1038/s41556-021-00654-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
54 Shimura T. Novel Biomarkers of Gastrointestinal Cancer. Cancers (Basel) 2021;13:1501. [PMID: 33805858 DOI: 10.3390/cancers13071501] [Reference Citation Analysis]
55 Mauri G, Bonazzina E, Amatu A, Tosi F, Bencardino K, Gori V, Massihnia D, Cipani T, Spina F, Ghezzi S, Siena S, Sartore-Bianchi A. The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:E137. [PMID: 33406649 DOI: 10.3390/cancers13010137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
56 Rohatgi A, Govindan R. Targeting KRAS G12C mutation in lung adenocarcinoma. Lung Cancer 2022;165:28-33. [DOI: 10.1016/j.lungcan.2021.12.021] [Reference Citation Analysis]
57 Wang CJ, Brownell I. BRAF Inhibitors for the Treatment of Papulopustular Eruptions from MAPK Pathway Inhibitors. Am J Clin Dermatol 2020;21:759-64. [PMID: 32720072 DOI: 10.1007/s40257-020-00539-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Song J, Kataoka K, Yamada T, Shiozawa M, Sonoyama T, Beppu N, Ueda K, Kuriyama S, Kanazawa A, Ikeda M, Ceelen W. The impact of molecular profile on the lymphatic spread pattern in stage III colon cancer. Cancer Sci 2021;112:1545-55. [PMID: 33484192 DOI: 10.1111/cas.14819] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Hasbullah HH, Musa M. Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward? Int J Mol Sci 2021;22:11941. [PMID: 34769370 DOI: 10.3390/ijms222111941] [Reference Citation Analysis]
60 Sveen A, Johannessen B, Eilertsen IA, Røsok BI, Gulla M, Eide PW, Bruun J, Kryeziu K, Meza-Zepeda LA, Myklebost O, Bjørnbeth BA, Skotheim RI, Nesbakken A, Lothe RA. The expressed mutational landscape of microsatellite stable colorectal cancers. Genome Med 2021;13:142. [PMID: 34470667 DOI: 10.1186/s13073-021-00955-2] [Reference Citation Analysis]
61 Zhou J, Ji Q, Li Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. J Exp Clin Cancer Res 2021;40:328. [PMID: 34663410 DOI: 10.1186/s13046-021-02130-2] [Reference Citation Analysis]
62 Nie S, Yang G, Lu H. Current Molecular Targeted Agents for Advanced Gastric Cancer. Onco Targets Ther. 2020;13:4075-4088. [PMID: 32494161 DOI: 10.2147/ott.s246412] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
63 Wang Z, Kang B, Gao Q, Huang L, Di J, Fan Y, Yu J, Jiang B, Gao F, Wang D, Sun H, Gu Y, Li J, Su X. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells. Cancer Sci 2021;112:3895-910. [PMID: 34185934 DOI: 10.1111/cas.15049] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Xu Z, Peng X, Kong Y, Cui Y, Li Y, Guo Y. The best strategy for metastatic colorectal cancer (mCRC) patients in second-line treatment: A network meta-analysis. Cancer Treat Res Commun 2021;29:100455. [PMID: 34619647 DOI: 10.1016/j.ctarc.2021.100455] [Reference Citation Analysis]
65 Chu JE, Johnson B, Kugathasan L, Morris VK, Raghav K, Swanson L, Lim HJ, Renouf DJ, Gill S, Wolber R, Karsan A, Kopetz S, Schaeffer DF, Loree JM. Population-based Screening for BRAF V600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis. Clin Cancer Res 2020;26:4599-605. [PMID: 32571791 DOI: 10.1158/1078-0432.CCR-20-1024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
66 García-Alfonso P, García-Carbonero R, García-Foncillas J, Pérez-Segura P, Salazar R, Vera R, Ramón Y Cajal S, Hernández-Losa J, Landolfi S, Musulén E, Cuatrecasas M, Navarro S. Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol 2020;22:1976-91. [PMID: 32418154 DOI: 10.1007/s12094-020-02357-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Moskovich D, Finkelshtein Y, Alfandari A, Rosemarin A, Lifschytz T, Weisz A, Mondal S, Ungati H, Katzav A, Kidron D, Mugesh G, Ellis M, Lerer B, Ashur-Fabian O. Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment. Oncogene 2021;40:6248-57. [PMID: 34556811 DOI: 10.1038/s41388-021-02020-z] [Reference Citation Analysis]
68 Karimi M, Wang C, Bahadini B, Hajjar G, Fakih M. Integrating Academic and Community Practices in the Management of Colorectal Cancer: The City of Hope Model. J Clin Med 2020;9:E1687. [PMID: 32498251 DOI: 10.3390/jcm9061687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Li Wan Po A. Genomic research delivering on promises: From rejuvenation to vaccines and pharmacogenetics. J Clin Pharm Ther 2020;45:585-9. [PMID: 32187712 DOI: 10.1111/jcpt.13131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Foster J, Freidlin B, Korn EL, Smith M. Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity. ESMO Open 2020;5:e000871. [PMID: 33122353 DOI: 10.1136/esmoopen-2020-000871] [Reference Citation Analysis]
71 Thomas V, Cotter MB, Tosetto M, Khaw YL, Geraghty R, Winter DC, Ryan EJ, Sheahan K, Furney SJ. Personalised mapping of tumour development in synchronous colorectal cancer patients. NPJ Genom Med 2020;5:27. [PMID: 32655884 DOI: 10.1038/s41525-020-0134-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Guo Y, Wang S, Zhao ZY, Li JN, Shang A, Li DL, Wang M. Skeletal muscle metastasis with bone metaplasia from colon cancer: A case report and review of the literature. World J Clin Cases 2021; 9(30): 9285-9294 [PMID: 34786415 DOI: 10.12998/wjcc.v9.i30.9285] [Reference Citation Analysis]
73 Tabernero J, Velez L, Trevino TL, Grothey A, Yaeger R, Van Cutsem E, Wasan H, Desai J, Ciardiello F, Yoshino T, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. ESMO Open 2021;6:100328. [PMID: 34896698 DOI: 10.1016/j.esmoop.2021.100328] [Reference Citation Analysis]
74 Moati E, Taly V, Garinet S, Didelot A, Taieb J, Laurent-Puig P, Zaanan A. Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives. Cancers (Basel) 2021;13:4743. [PMID: 34638228 DOI: 10.3390/cancers13194743] [Reference Citation Analysis]
75 Hervieu C, Christou N, Battu S, Mathonnet M. The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials. Cancers (Basel) 2021;13:1092. [PMID: 33806312 DOI: 10.3390/cancers13051092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
76 Xu SF, Guo Y, Zhang X, Zhu XD, Fan N, Zhang ZL, Ren GB, Rao W, Zang YJ. Somatic Mutation Profiling of Intrahepatic Cholangiocarcinoma: Comparison between Primary and Metastasis Tumor Tissues. J Oncol 2020;2020:5675020. [PMID: 33014052 DOI: 10.1155/2020/5675020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Angerilli V, Galuppini F, Pagni F, Fusco N, Malapelle U, Fassan M. The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization. Diagnostics (Basel) 2021;11:339. [PMID: 33670699 DOI: 10.3390/diagnostics11020339] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
78 Park R, Lopes L, Lee S, Riano I, Saeed A. The prognostic and predictive impact of BRAF mutations in deficient mismatch repair/microsatellite instability-high colorectal cancer: systematic review/meta-analysis. Future Oncol 2021;17:4221-31. [PMID: 34323124 DOI: 10.2217/fon-2021-0552] [Reference Citation Analysis]
79 Kobayashi S, Takahashi S, Nomura S, Kojima M, Kudo M, Sugimoto M, Konishi M, Gotohda N, Taniguchi H, Yoshino T. BRAF V600E potentially determines "Oncological Resectability" for "Technically Resectable" colorectal liver metastases. Cancer Med 2021;10:6998-7011. [PMID: 34535965 DOI: 10.1002/cam4.4227] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
80 Geyer N, Gerling M. Hedgehog Signaling in Colorectal Cancer: All in the Stroma? Int J Mol Sci 2021;22:1025. [PMID: 33498528 DOI: 10.3390/ijms22031025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Nakayama I, Hirota T, Shinozaki E. BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Cancers (Basel) 2020;12:E3236. [PMID: 33152998 DOI: 10.3390/cancers12113236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
82 Hidaka A, Harrison TA, Cao Y, Sakoda LC, Barfield R, Giannakis M, Song M, Phipps AI, Figueiredo JC, Zaidi SH, Toland AE, Amitay EL, Berndt SI, Borozan I, Chan AT, Gallinger S, Gunter MJ, Guinter MA, Harlid S, Hampel H, Jenkins MA, Lin Y, Moreno V, Newcomb PA, Nishihara R, Ogino S, Obón-Santacana M, Parfrey PS, Potter JD, Slattery ML, Steinfelder RS, Um CY, Wang X, Woods MO, Van Guelpen B, Thibodeau SN, Hoffmeister M, Sun W, Hsu L, Buchanan DD, Campbell PT, Peters U. Intake of Dietary Fruit, Vegetables, and Fiber and Risk of Colorectal Cancer According to Molecular Subtypes: A Pooled Analysis of 9 Studies. Cancer Res 2020;80:4578-90. [PMID: 32816852 DOI: 10.1158/0008-5472.CAN-20-0168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
83 Czauderna C, Kirstein MM, Tews HC, Vogel A, Marquardt JU. Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2803. [PMID: 34202401 DOI: 10.3390/jcm10132803] [Reference Citation Analysis]
84 Adamopoulos C, Ahmed TA, Tucker MR, Ung PMU, Xiao M, Karoulia Z, Amabile A, Wu X, Aaronson SA, Ang C, Rebecca VW, Brown BD, Schlessinger A, Herlyn M, Wang Q, Shaw DE, Poulikakos PI. Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. Cancer Discov 2021;11:1716-35. [PMID: 33568355 DOI: 10.1158/2159-8290.CD-20-1351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
85 Baur F, Nietzer SL, Kunz M, Saal F, Jeromin J, Matschos S, Linnebacher M, Walles H, Dandekar T, Dandekar G. Connecting Cancer Pathways to Tumor Engines: A Stratification Tool for Colorectal Cancer Combining Human In Vitro Tissue Models with Boolean In Silico Models. Cancers (Basel) 2019;12:E28. [PMID: 31861874 DOI: 10.3390/cancers12010028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
86 Akhave NS, Biter AB, Hong DS. Mechanisms of Resistance to KRASG12C-Targeted Therapy. Cancer Discov 2021;11:1345-52. [PMID: 33820777 DOI: 10.1158/2159-8290.CD-20-1616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
87 Kotani D, Bando H, Taniguchi H, Masuishi T, Komatsu Y, Yamaguchi K, Nakajima T, Satoh T, Nishina T, Esaki T, Nomura S, Takahashi K, Iida S, Matsuda S, Motonaga S, Fuse N, Sato A, Fujii S, Ohtsu A, Ebi H, Yoshino T. BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer. ESMO Open 2020;5:e000624. [PMID: 33551068 DOI: 10.1136/esmoopen-2019-000624] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Addeo A, Banna GL, Friedlaender A. KRAS G12C Mutations in NSCLC: From Target to Resistance. Cancers (Basel) 2021;13:2541. [PMID: 34064232 DOI: 10.3390/cancers13112541] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
89 Fassan M, Scarpa A, Remo A, De Maglio G, Troncone G, Marchetti A, Doglioni C, Ingravallo G, Perrone G, Parente P, Luchini C, Mastracci L. Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice. Pathologica 2020;112:248-59. [PMID: 33179625 DOI: 10.32074/1591-951X-158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
90 Zhuang Y, Wang H, Jiang D, Li Y, Feng L, Tian C, Pu M, Wang X, Zhang J, Hu Y, Liu P. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis. BMC Cancer 2021;21:380. [PMID: 33836681 DOI: 10.1186/s12885-021-08108-9] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
91 Baraibar I, Mirallas O, Saoudi N, Ros J, Salvà F, Tabernero J, Élez E. Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:6311. [PMID: 34944931 DOI: 10.3390/cancers13246311] [Reference Citation Analysis]
92 Sammarco G, Gallo G, Vescio G, Picciariello A, De Paola G, Trompetto M, Currò G, Ammendola M. Mast Cells, microRNAs and Others: The Role of Translational Research on Colorectal Cancer in the Forthcoming Era of Precision Medicine. J Clin Med 2020;9:E2852. [PMID: 32899322 DOI: 10.3390/jcm9092852] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
93 Lisby AN, Flickinger JC Jr, Bashir B, Weindorfer M, Shelukar S, Crutcher M, Snook AE, Waldman SA. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Rev Precis Med Drug Dev 2021;6:117-29. [PMID: 34027103 DOI: 10.1080/23808993.2021.1876518] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Petrowsky H, Fritsch R, Guckenberger M, De Oliveira ML, Dutkowski P, Clavien P. Modern therapeutic approaches for the treatment of malignant liver tumours. Nat Rev Gastroenterol Hepatol 2020;17:755-72. [DOI: 10.1038/s41575-020-0314-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
95 Liu Y, Zhang X, Zhang J, Tan J, Li J, Song Z. Development and Validation of a Combined Ferroptosis and Immune Prognostic Classifier for Hepatocellular Carcinoma. Front Cell Dev Biol 2020;8:596679. [PMID: 33425905 DOI: 10.3389/fcell.2020.596679] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
96 Yu IS, Loree JM. FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left-Sided RAS/BRAF Wild-Type Colorectal Cancer: Which "Side" Are You On? Oncologist 2021;26:277-80. [PMID: 33539032 DOI: 10.1002/onco.13705] [Reference Citation Analysis]
97 Bellio H, Fumet JD, Ghiringhelli F. Targeting BRAF and RAS in Colorectal Cancer. Cancers (Basel) 2021;13:2201. [PMID: 34063682 DOI: 10.3390/cancers13092201] [Reference Citation Analysis]
98 Iwasaki E, Fukuhara S, Horibe M, Kawasaki S, Seino T, Takimoto Y, Tamagawa H, Machida Y, Kayashima A, Noda M, Hayashi H, Kanai T. Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment. Diagnostics (Basel) 2021;11:469. [PMID: 33800161 DOI: 10.3390/diagnostics11030469] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Schneeweis C, Hassan Z, Schick M, Keller U, Schneider G. The SUMO pathway in pancreatic cancer: insights and inhibition. Br J Cancer 2021;124:531-8. [PMID: 33071285 DOI: 10.1038/s41416-020-01119-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
100 Moosavi SH, Eide PW, Eilertsen IA, Brunsell TH, Berg KCG, Røsok BI, Brudvik KW, Bjørnbeth BA, Guren MG, Nesbakken A, Lothe RA, Sveen A. De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity. Genome Med 2021;13:143. [PMID: 34470666 DOI: 10.1186/s13073-021-00956-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Rumpold H, Niedersüß-Beke D, Heiler C, Falch D, Wundsam HV, Metz-Gercek S, Piringer G, Thaler J. Prediction of mortality in metastatic colorectal cancer in a real-life population: a multicenter explorative analysis. BMC Cancer 2020;20:1149. [PMID: 33238958 DOI: 10.1186/s12885-020-07656-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Canale M, Monti M, Rapposelli IG, Ulivi P, Sullo FG, Bartolini G, Tiberi E, Frassineti GL. Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer. Cancers (Basel) 2021;13:5671. [PMID: 34830826 DOI: 10.3390/cancers13225671] [Reference Citation Analysis]
103 Lai E, Liscia N, Donisi C, Mariani S, Tolu S, Pretta A, Persano M, Pinna G, Balconi F, Pireddu A, Impera V, Dubois M, Migliari M, Spanu D, Saba G, Camera S, Musio F, Ziranu P, Puzzoni M, Demurtas L, Pusceddu V, Dettori M, Massa E, Atzori F, Dessì M, Astara G, Madeddu C, Scartozzi M. Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E1214. [PMID: 32413973 DOI: 10.3390/cancers12051214] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
104 Lavacchi D, Roviello G, D'Angelo A. Tumor-Agnostic Treatment for Cancer: When How is Better than Where. Clin Drug Investig 2020;40:519-27. [PMID: 32307639 DOI: 10.1007/s40261-020-00915-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
105 Hescheler DA, Riemann B, Hartmann MJM, Michel M, Faust M, Bruns CJ, Alakus H, Chiapponi C. Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis. Front Endocrinol (Lausanne) 2021;12:748941. [PMID: 34630336 DOI: 10.3389/fendo.2021.748941] [Reference Citation Analysis]
106 Stein MK, Oluoha O, Patel K, VanderWalde A. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. J Pers Med 2021;11:518. [PMID: 34198738 DOI: 10.3390/jpm11060518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Bruun J, Eide PW, Bergsland CH, Bruck O, Svindland A, Arjama M, Välimäki K, Bjørnslett M, Guren MG, Kallioniemi O, Nesbakken A, Lothe RA, Pellinen T. E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models. Mol Oncol 2021. [PMID: 34890102 DOI: 10.1002/1878-0261.13159] [Reference Citation Analysis]
108 Martínez-Lago N, Fernández-Montes A, Covela M, Brozos EM, De la Cámara J, Méndez Méndez JC, Jorge-Fernández M, Cousillas Castiñeiras A, Reboredo C, Arias Ron D, Pellón Augusto ML, González Villarroel P, Graña B, Salgado Fernández M, Carral Maseda A, Vázquez Rivera F, Candamio Folgar S, Reboredo López M; Galician Research Group on Digestive Tumors (GITuD). Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain. BMC Cancer 2021;21:64. [PMID: 33446148 DOI: 10.1186/s12885-020-07758-5] [Reference Citation Analysis]
109 Howe JR. The impact of DNA testing on management of patients with colorectal cancer. Ann Gastroenterol Surg. [DOI: 10.1002/ags3.12526] [Reference Citation Analysis]
110 Osumi H, Muroi A, Sakahara M, Kawachi H, Okamoto T, Natsume Y, Yamanaka H, Takano H, Kusama D, Shinozaki E, Ooki A, Yamaguchi K, Ueno M, Takeuchi K, Noda T, Nagayama S, Koshikawa N, Yao R. Evaluation of the RAS signaling network in response to MEK inhibition using organoids derived from a familial adenomatous polyposis patient. Sci Rep 2020;10:17455. [PMID: 33060766 DOI: 10.1038/s41598-020-74530-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Jalali A, Gard G, Banks S, Dunn C, Wong HL, Wong R, Lee M, Gately L, Loft M, Shapiro JD, Kosmider S, Tie J, Ananda S, Yeung JM, Jennens R, Lee B, McKendrick J, Lim L, Khattak A, Gibbs P. Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. Curr Probl Cancer 2021;:100793. [PMID: 34565601 DOI: 10.1016/j.currproblcancer.2021.100793] [Reference Citation Analysis]
112 Personeni N, Smiroldo V, Giunta EF, Prete MG, Rimassa L, Bregni G, Sclafani F. Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives. Cancers (Basel) 2021;13:4506. [PMID: 34572729 DOI: 10.3390/cancers13184506] [Reference Citation Analysis]
113 Cherri S, Libertini M, Zaniboni A. New drugs for the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2021; 13(11): 1551-1560 [PMID: 34853636 DOI: 10.4251/wjgo.v13.i11.1551] [Reference Citation Analysis]
114 Min BJ, Lee WS, Seo ME, Lee KH, Jeong SY, Ku JL, Kim YH, Shin SW, Kim JH. Development and Validation of Targeted Gene Sequencing Panel Based Companion Diagnostic for Korean Patients with Solid Tumors. Cancers (Basel) 2021;13:5112. [PMID: 34680263 DOI: 10.3390/cancers13205112] [Reference Citation Analysis]
115 Huang YH, Lin PC, Su WC, Chan RH, Chen PC, Lin BW, Shen MR, Chen SH, Yeh YM. Association between Altered Oncogenic Signaling Pathways and Overall Survival of Patients with Metastatic Colorectal Cancer. Diagnostics (Basel) 2021;11:2308. [PMID: 34943546 DOI: 10.3390/diagnostics11122308] [Reference Citation Analysis]
116 Manca P, Corallo S, Lonardi S, Fucà G, Busico A, Leone AG, Corti F, Antoniotti C, Procaccio L, Smiroldo V, Ratti M, Murialdo R, Racca P, Pagani F, Randon G, Martinetti A, Sottotetti E, Prisciandaro M, Ambrosini M, Raimondi A, Morano F, Pietrantonio F. Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study. Br J Cancer 2021. [PMID: 34811502 DOI: 10.1038/s41416-021-01591-8] [Reference Citation Analysis]
117 Damato A, Bergamo F, Antonuzzo L, Nasti G, Iachetta F, Romagnani A, Gervasi E, Larocca M, Pinto C. FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial. Front Oncol 2021;11:766500. [PMID: 34970487 DOI: 10.3389/fonc.2021.766500] [Reference Citation Analysis]
118 Middleton G, Robbins H, Andre F, Swanton C. A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer. Ann Oncol 2021:S0923-7534(21)04785-2. [PMID: 34808340 DOI: 10.1016/j.annonc.2021.11.004] [Reference Citation Analysis]
119 Walter T, Hawkins NS, Pollock RF, Colaone F, Shergill S, Ross PJ. Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. J Cancer Res Clin Oncol 2020;146:2575-87. [PMID: 32715436 DOI: 10.1007/s00432-020-03315-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
120 El Bali M, Bakkach J, Bennani Mechita M. Colorectal Cancer: From Genetic Landscape to Targeted Therapy. J Oncol 2021;2021:9918116. [PMID: 34326875 DOI: 10.1155/2021/9918116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
121 Hamre TR, Stougaard JK, Havelund BM, Jensen LH, Hansen TF. Re-exposure to immunotherapy in metastatic colon cancer: A case report. Clin Case Rep 2021;9:e04349. [PMID: 34194811 DOI: 10.1002/ccr3.4349] [Reference Citation Analysis]
122 Tomasini PP, Guecheva TN, Leguisamo NM, Péricart S, Brunac AC, Hoffmann JS, Saffi J. Analyzing the Opportunities to Target DNA Double-Strand Breaks Repair and Replicative Stress Responses to Improve Therapeutic Index of Colorectal Cancer. Cancers (Basel) 2021;13:3130. [PMID: 34201502 DOI: 10.3390/cancers13133130] [Reference Citation Analysis]
123 Buikhuisen JY, Torang A, Medema JP. Exploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges. Oncogenesis 2020;9:66. [PMID: 32647253 DOI: 10.1038/s41389-020-00250-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
124 Zhang Y, Zhao Y, Li Q, Wang Y. Macrophages, as a Promising Strategy to Targeted Treatment for Colorectal Cancer Metastasis in Tumor Immune Microenvironment. Front Immunol 2021;12:685978. [PMID: 34326840 DOI: 10.3389/fimmu.2021.685978] [Reference Citation Analysis]
125 Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol 2020;13:143. [PMID: 33109256 DOI: 10.1186/s13045-020-00977-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
126 Chung C. Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation. J Oncol Pharm Pract 2021;:10781552211005525. [PMID: 33832365 DOI: 10.1177/10781552211005525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 John L, Krauth MT, Podar K, Raab MS. Pathway-Directed Therapy in Multiple Myeloma. Cancers (Basel) 2021;13:1668. [PMID: 33916289 DOI: 10.3390/cancers13071668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Boilève A, Samalin E. [New drug approval: Encorafenib-metastatic colorectal cancers with BRAF V600E mutation after systemic chemotherapy]. Bull Cancer 2020;107:1086-8. [PMID: 33046237 DOI: 10.1016/j.bulcan.2020.08.012] [Reference Citation Analysis]
129 Parisi A, Porzio G, Pulcini F, Cannita K, Ficorella C, Mattei V, Delle Monache S. What Is Known about Theragnostic Strategies in Colorectal Cancer. Biomedicines 2021;9:140. [PMID: 33535557 DOI: 10.3390/biomedicines9020140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
130 Mascarenhas L. A Step Forward in Realizing the Promise of Genomic Medicine for Childhood Rhabdomyosarcoma. J Clin Oncol 2021;39:2851-4. [PMID: 34181486 DOI: 10.1200/JCO.21.01296] [Reference Citation Analysis]
131 Takemasa I, Hamabe A, Ishii M. Perspectives for circulating tumor DNA in clinical management of colorectal cancer. Int J Clin Oncol 2021;26:1420-30. [PMID: 34185174 DOI: 10.1007/s10147-021-01937-5] [Reference Citation Analysis]
132 Pickles OJ, Drozd A, Tee L, Beggs AD, Middleton GW. Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer. Oncotarget 2020;11:3188-97. [PMID: 32922659 DOI: 10.18632/oncotarget.27681] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
133 Tan AC, Bagley SJ, Wen PY, Lim M, Platten M, Colman H, Ashley DM, Wick W, Chang SM, Galanis E, Mansouri A, Khagi S, Mehta MP, Heimberger AB, Puduvalli VK, Reardon DA, Sahebjam S, Simes J, Antonia SJ, Berry D, Khasraw M. Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. J Immunother Cancer 2021;9:e002459. [PMID: 34215688 DOI: 10.1136/jitc-2021-002459] [Reference Citation Analysis]
134 Weng S, Yuan Y, Wang X, Chen G, Wang Y, Sheng W, Li X, Zhou A, Zhang Z, Li G, Cai S, Xu R, Li J, Zhang S. Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019. Chin J Cancer Res 2020;32:403-7. [PMID: 32694904 DOI: 10.21147/j.issn.1000-9604.2020.03.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
135 Wang C, Cao Y, Yang C, Bernards R, Qin W. Exploring liver cancer biology through functional genetic screens. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34163045 DOI: 10.1038/s41575-021-00465-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
136 Luo W, Liu Q, Chen X, Liu H, Quan B, Lu J, Zhang K, Wang X. FXYD6 Regulates Chemosensitivity by Mediating the Expression of Na+/K+-ATPase α1 and Affecting Cell Autophagy and Apoptosis in Colorectal Cancer. Biomed Res Int 2021;2021:9986376. [PMID: 34212047 DOI: 10.1155/2021/9986376] [Reference Citation Analysis]
137 Hussen BM, Abdullah ST, Salihi A, Sabir DK, Sidiq KR, Rasul MF, Hidayat HJ, Ghafouri-Fard S, Taheri M, Jamali E. The emerging roles of NGS in clinical oncology and personalized medicine. Pathol Res Pract 2022;230:153760. [PMID: 35033746 DOI: 10.1016/j.prp.2022.153760] [Reference Citation Analysis]
138 Rossini D, Lonardi S, Antoniotti C, Santini D, Tomasello G, Ermacora P, Germani MM, Bergamo F, Ricci V, Caponnetto S, Moretto R, Zaniboni A, Pietrantonio F, Buonadonna A, Ritorto G, Masi G, Latiano TP, Rapisardi S, Falcone A, Cremolini C. Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO. Br J Cancer 2021;124:183-90. [PMID: 33024268 DOI: 10.1038/s41416-020-01089-9] [Reference Citation Analysis]
139 Djanani A, Eller S, Öfner D, Troppmair J, Maglione M. The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future. Int J Mol Sci 2020;21:E9001. [PMID: 33256240 DOI: 10.3390/ijms21239001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
140 Giordano G, Parcesepe P, Bruno G, Piscazzi A, Lizzi V, Remo A, Pancione M, D'Andrea MR, De Santis E, Coppola L, Pietrafesa M, Fersini A, Ambrosi A, Landriscina M. Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. Int J Mol Sci 2021;22:7717. [PMID: 34299337 DOI: 10.3390/ijms22147717] [Reference Citation Analysis]
141 Busch E, Kreutzfeldt S, Agaimy A, Mechtersheimer G, Horak P, Brors B, Hutter B, Fröhlich M, Uhrig S, Mayer P, Schröck E, Stenzinger A, Glimm H, Jäger D, Springfeld C, Fröhling S, Zschäbitz S. Successful BRAF/MEK inhibition in a patient with BRAF V600E-mutated extrapancreatic acinar cell carcinoma. Cold Spring Harb Mol Case Stud 2020;6:a005553. [PMID: 32843432 DOI: 10.1101/mcs.a005553] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
142 Hofheinz RD, Stintzing S. [Personalized systemic treatment of metastatic colorectal cancer]. Internist (Berl) 2020;61:699-710. [PMID: 32494899 DOI: 10.1007/s00108-020-00808-x] [Reference Citation Analysis]
143 Kato S, Okamura R, Adashek JJ, Khalid N, Lee S, Nguyen V, Sicklick JK, Kurzrock R. Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens. JCI Insight 2021;6:142547. [PMID: 33427211 DOI: 10.1172/jci.insight.142547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Rao L, Giannico D, Leone P, Solimando AG, Maiorano E, Caporusso C, Duda L, Tamma R, Mallamaci R, Susca N, Buonavoglia A, Da Vià MC, Ribatti D, De Re V, Vacca A, Racanelli V. HB-EGF-EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma. Cancers (Basel) 2020;12:E173. [PMID: 31936715 DOI: 10.3390/cancers12010173] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
145 Johnson KA, DeStefanis RA, Emmerich PB, Grogan PT, Kratz JD, Makkar SK, Clipson L, Deming DA. Human Colon Organoids and Other Laboratory Strategies to Enhance Patient Treatment Selection. Curr Treat Options Oncol 2020;21:35. [PMID: 32328818 DOI: 10.1007/s11864-020-00737-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
146 Su M, Zhan L, Zhang Y, Zhang J. Yes-activated protein promotes primary resistance of BRAF V600E mutant metastatic colorectal cancer cells to mitogen-activated protein kinase pathway inhibitors. J Gastrointest Oncol 2021;12:953-63. [PMID: 34295548 DOI: 10.21037/jgo-21-258] [Reference Citation Analysis]
147 Hummel M, Hegewisch-Becker S, Neumann JHL, Vogel A. BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options. Pathologe 2021. [PMID: 34259881 DOI: 10.1007/s00292-021-00946-5] [Reference Citation Analysis]
148 Gambardella V, Tarazona N, Cejalvo JM, Lombardi P, Huerta M, Roselló S, Fleitas T, Roda D, Cervantes A. Personalized Medicine: Recent Progress in Cancer Therapy. Cancers (Basel) 2020;12:E1009. [PMID: 32325878 DOI: 10.3390/cancers12041009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
149 Tsakiraki Z, Delides A, Damaskou V, Psarogiorgou S, Athanasiadis I, Spathis A, Giotakis E, Panayiotides IG. Palatine tonsil metastasis of cecal mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN): A unique case. Clin Case Rep 2021;9:e04460. [PMID: 34295485 DOI: 10.1002/ccr3.4460] [Reference Citation Analysis]
150 Kazama K, Shiozawa M, Numata M, Sugano N, Sato S, Uchiyama M, Sato M, Aoyama T, Tamagawa H, Oshima T, Yukawa N, Rino Y. Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice. Int J Colorectal Dis 2021. [PMID: 34767074 DOI: 10.1007/s00384-021-04064-9] [Reference Citation Analysis]
151 Green MF, Bell JL, Hubbard CB, McCall SJ, McKinney MS, Riedel JE, Menendez CS, Abbruzzese JL, Strickler JH, Datto MB. Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience. JCO Precis Oncol 2021;5:PO. [PMID: 34568718 DOI: 10.1200/PO.21.00030] [Reference Citation Analysis]
152 Lam M, Lum C, Latham S, Tipping Smith S, Prenen H, Segelov E. Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects. Cancer Manag Res 2020;12:5819-30. [PMID: 32765085 DOI: 10.2147/CMAR.S213236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
153 Johnson DB, Nebhan CA, Noel MS. MEK inhibitors in non-V600 BRAF mutations and fusions. Oncotarget 2020;11:3900-3. [PMID: 33216832 DOI: 10.18632/oncotarget.27788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Patel KK, Stein S, Lacy J, O'Hara M, Huntington SF. Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer. JAMA Netw Open 2021;4:e2033441. [PMID: 33433598 DOI: 10.1001/jamanetworkopen.2020.33441] [Reference Citation Analysis]
155 Kim SY, Kim TW. Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. ESMO Open 2020;5:e000634. [PMID: 32188714 DOI: 10.1136/esmoopen-2019-000634] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
156 Cimino SK, Eng C. Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer. J Exp Pharmacol 2020;12:475-85. [PMID: 33204182 DOI: 10.2147/JEP.S259287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
157 Ros J, Baraibar I, Sardo E, Mulet N, Salvà F, Argilés G, Martini G, Ciardiello D, Cuadra JL, Tabernero J, Élez E. BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer. Ther Adv Med Oncol 2021;13:1758835921992974. [PMID: 33747149 DOI: 10.1177/1758835921992974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
158 Durinikova E, Buzo K, Arena S. Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges. J Exp Clin Cancer Res 2021;40:185. [PMID: 34090508 DOI: 10.1186/s13046-021-01981-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
159 Caputo F, Santini C, Bardasi C, Cerma K, Casadei-Gardini A, Spallanzani A, Andrikou K, Cascinu S, Gelsomino F. BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. Int J Mol Sci. 2019;20. [PMID: 31661924 DOI: 10.3390/ijms20215369] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
160 Ebi H, Bando H, Taniguchi H, Sunakawa Y, Okugawa Y, Hatanaka Y, Hosoda W, Kumamoto K, Nakatani K, Yamazaki K. Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition. Cancer Sci. 2020; Epub ahead of print. [PMID: 32667108 DOI: 10.1111/cas.14567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
161 Roviello G, D'Angelo A, Sirico M, Pittacolo M, Conter FU, Sobhani N. Advances in anti-BRAF therapies for lung cancer. Invest New Drugs 2021;39:879-90. [PMID: 33474634 DOI: 10.1007/s10637-021-01068-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
162 Marin JJG, Macias RIR, Monte MJ, Herraez E, Peleteiro-Vigil A, Blas BS, Sanchon-Sanchez P, Temprano AG, Espinosa-Escudero RA, Lozano E, Briz O, Romero MR. Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment. Cancers (Basel) 2020;12:E2605. [PMID: 32933095 DOI: 10.3390/cancers12092605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
163 Koncina E, Haan S, Rauh S, Letellier E. Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges. Cancers (Basel). 2020;12. [PMID: 32019056 DOI: 10.3390/cancers12020319] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
164 Miele E, Abballe L, Spinelli GP, Besharat ZM, Catanzaro G, Chiacchiarini M, Vacca A, Po A, Capalbo C, Ferretti E. BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors. BMC Cancer 2020;20:129. [PMID: 32066410 DOI: 10.1186/s12885-020-6586-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
165 Chowdhury S, Hofree M, Lin K, Maru D, Kopetz S, Shen JP. Implications of Intratumor Heterogeneity on Consensus Molecular Subtype (CMS) in Colorectal Cancer. Cancers (Basel) 2021;13:4923. [PMID: 34638407 DOI: 10.3390/cancers13194923] [Reference Citation Analysis]
166 Liposits G, Eshøj HR, Möller S, Winther SB, Skuladottir H, Ryg J, Hofsli E, Shah CH, Poulsen LØ, Berglund Å, Qvortrup C, Österlund P, Glimelius B, Sorbye H, Pfeiffer P. Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study. Cancers (Basel) 2021;13:2604. [PMID: 34073363 DOI: 10.3390/cancers13112604] [Reference Citation Analysis]
167 Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol 2021;39:273-84. [PMID: 33503393 DOI: 10.1200/JCO.20.02088] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 16.0] [Reference Citation Analysis]
168 Calegari MA, Salvatore L, Di Stefano B, Basso M, Orlandi A, Boccaccino A, Lombardo F, Auriemma A, Zurlo IV, Bensi M, Camarda F, Ribelli M, Vivolo R, Cocomazzi A, Pozzo C, Milella M, Martini M, Bria E, Tortora G. Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study). Cancers (Basel) 2021;13:2098. [PMID: 33925278 DOI: 10.3390/cancers13092098] [Reference Citation Analysis]
169 Papamichail M, Pizanias M, Heaton ND, M P, M P, Nd H. Minimizing the risk of small-for-size syndrome after liver surgery. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00230-7. [PMID: 34961675 DOI: 10.1016/j.hbpd.2021.12.005] [Reference Citation Analysis]
170 Ji J, Wang C, Fakih M. Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAF Mutation Who Progressed on Cetuximab and Encorafenib With or Without Binimetinib: A Case Series. Clinical Colorectal Cancer 2021. [DOI: 10.1016/j.clcc.2021.12.001] [Reference Citation Analysis]
171 Folprecht G, Martinelli E, Mazard T, Modest DP, Tsuji A, Esser R, Cremolini C, Falcone A. Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. Cancer Treat Rev 2022;102:102301. [PMID: 34839118 DOI: 10.1016/j.ctrv.2021.102301] [Reference Citation Analysis]
172 Chakravarty D, Solit DB. Clinical cancer genomic profiling. Nat Rev Genet 2021;22:483-501. [PMID: 33762738 DOI: 10.1038/s41576-021-00338-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
173 Kim K, Khang D. Past, Present, and Future of Anticancer Nanomedicine. Int J Nanomedicine 2020;15:5719-43. [PMID: 32821098 DOI: 10.2147/IJN.S254774] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
174 De Falco V, Napolitano S, Roselló S, Huerta M, Cervantes A, Ciardiello F, Troiani T. How we treat metastatic colorectal cancer. ESMO Open 2020;4:e000813. [PMID: 32817137 DOI: 10.1136/esmoopen-2020-000813] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
175 Bayle A, Basile D, Garinet S, Rance B, Laurent-Puig P, Blons H, Taieb J, Perkins G. Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers. Cancers (Basel) 2021;13:5750. [PMID: 34830904 DOI: 10.3390/cancers13225750] [Reference Citation Analysis]
176 Roviello G, D'Angelo A, Petrioli R, Roviello F, Cianchi F, Nobili S, Mini E, Lavacchi D. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. Transl Oncol 2020;13:100795. [PMID: 32470910 DOI: 10.1016/j.tranon.2020.100795] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
177 Corn BW, Feldman DB, Hull JG, O'Rourke MA, Bakitas MA. Dispositional hope as a potential outcome parameter among patients with advanced malignancy: An analysis of the ENABLE database. Cancer 2021. [PMID: 34613617 DOI: 10.1002/cncr.33907] [Reference Citation Analysis]
178 Lapucci A, Perrone G, Di Paolo A, Napoli C, Landini I, Roviello G, Calosi L, Naccarato AG, Falcone A, Bani D, Mini E, Nobili S. PNN and KCNQ1OT1 Can Predict the Efficacy of Adjuvant Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer Patients. Oncol Res 2021;28:631-44. [PMID: 33208224 DOI: 10.3727/096504020X16056983169118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
179 Riedesser JE, Ebert MP, Betge J. Precision medicine for metastatic colorectal cancer in clinical practice. Ther Adv Med Oncol 2022;14:175883592110727. [DOI: 10.1177/17588359211072703] [Reference Citation Analysis]
180 Gerosa L, Chidley C, Fröhlich F, Sanchez G, Lim SK, Muhlich J, Chen JY, Vallabhaneni S, Baker GJ, Schapiro D, Atanasova MI, Chylek LA, Shi T, Yi L, Nicora CD, Claas A, Ng TSC, Kohler RH, Lauffenburger DA, Weissleder R, Miller MA, Qian WJ, Wiley HS, Sorger PK. Receptor-Driven ERK Pulses Reconfigure MAPK Signaling and Enable Persistence of Drug-Adapted BRAF-Mutant Melanoma Cells. Cell Syst 2020;11:478-494.e9. [PMID: 33113355 DOI: 10.1016/j.cels.2020.10.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
181 Gelsomino F, Casadei-Gardini A, Rossini D, Boccaccino A, Masi G, Cremolini C, Spallanzani A, Viola MG, Garajovà I, Salati M, Elia MT, Caputo F, Santini C, Falcone A, Cascinu S, Tamburini E. The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis. Cancers (Basel) 2020;12:E1022. [PMID: 32326305 DOI: 10.3390/cancers12041022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
182 Hummel M, Hegewisch-Becker S, Neumann J, Vogel A. [BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version]. Pathologe 2021. [PMID: 33956173 DOI: 10.1007/s00292-021-00942-9] [Reference Citation Analysis]
183 Saturno G, Lopes F, Niculescu-Duvaz I, Niculescu-Duvaz D, Zambon A, Davies L, Johnson L, Preece N, Lee R, Viros A, Holovanchuk D, Pedersen M, McLeary R, Lorigan P, Dhomen N, Fisher C, Banerji U, Dean E, Krebs MG, Gore M, Larkin J, Marais R, Springer C. The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers. Ann Oncol 2021;32:269-78. [PMID: 33130216 DOI: 10.1016/j.annonc.2020.10.483] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
184 Johnson B, Kopetz S. Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer.Target Oncol. 2020;15:567-577. [PMID: 32889679 DOI: 10.1007/s11523-020-00747-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
185 Galbraith NJ, Wood C, Steele CW. Targeting Metastatic Colorectal Cancer with Immune Oncological Therapies. Cancers (Basel) 2021;13:3566. [PMID: 34298779 DOI: 10.3390/cancers13143566] [Reference Citation Analysis]
186 Pietrantonio F, Morano F, Niger M, Corallo S, Antista M, Raimondi A, Prisciandaro M, Pagani F, Prinzi N, Nichetti F, Randon G, Torchio M, Corti F, Ambrosini M, Palermo F, Palazzo M, Biamonte L, Platania M, Sposito C, Cosimelli M, Mazzaferro V, Pusceddu S, Cremolini C, de Braud F, Di Bartolomeo M. Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. Clin Colorectal Cancer 2020;19:156-64. [PMID: 32513593 DOI: 10.1016/j.clcc.2020.05.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
187 Kurreck A, Geissler M, Martens UM, Riera-Knorrenschild J, Greeve J, Florschütz A, Wessendorf S, Ettrich T, Kanzler S, Nörenberg D, Seidensticker M, Held S, Buechner-Steudel P, Atzpodien J, Heinemann V, Stintzing S, Seufferlein T, Tannapfel A, Reinacher-Schick AC, Modest DP. Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109). J Cancer Res Clin Oncol 2020;146:2681-91. [PMID: 32449003 DOI: 10.1007/s00432-020-03257-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
188 García-Foncillas J, Argente J, Bujanda L, Cardona V, Casanova B, Fernández-Montes A, Horcajadas JA, Iñiguez A, Ortiz A, Pablos JL, Pérez Gómez MV. Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview. Mol Diagn Ther 2021;25:563-76. [PMID: 34331269 DOI: 10.1007/s40291-021-00544-4] [Reference Citation Analysis]
189 Salama AKS, Li S, Macrae ER, Park JI, Mitchell EP, Zwiebel JA, Chen HX, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Armstrong DK, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. J Clin Oncol 2020;38:3895-904. [PMID: 32758030 DOI: 10.1200/JCO.20.00762] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
190 Taieb J, Gallois C. Adjuvant Chemotherapy for Stage III Colon Cancer. Cancers (Basel) 2020;12:E2679. [PMID: 32961795 DOI: 10.3390/cancers12092679] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
191 Mukherji R, Marshall JL, Seeber A. Genomic Alterations and Their Implications on Survival in Nonmetastatic Colorectal Cancer: Status Quo and Future Perspectives. Cancers (Basel) 2020;12:E2001. [PMID: 32707813 DOI: 10.3390/cancers12082001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
192 Calegari MA, Stefano BD, Basso M, Carbone C, Camarda F, Ribelli M, Anghelone A, Vivolo R, Bensi M, Martini M, Pozzo C, Vellone M, Ardito F, Salvatore L, Giuliante F, Tortora G. Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report. Clin Colorectal Cancer 2021:S1533-0028(21)00088-8. [PMID: 34629317 DOI: 10.1016/j.clcc.2021.09.002] [Reference Citation Analysis]
193 Chan RH, Lin PC, Chen SH, Lin SC, Chen PC, Lin BW, Shen MR, Yeh YM. Clinical Utility of a Cell-Free DNA Assay in Patients With Colorectal Cancer. Front Oncol 2021;11:589673. [PMID: 33816227 DOI: 10.3389/fonc.2021.589673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
194 Zeng H, You C, Zhao L, Wang J, Ye X, Yang T, Wan C, Deng L. Ferroptosis-Associated Classifier and Indicator for Prognostic Prediction in Cutaneous Melanoma. J Oncol 2021;2021:3658196. [PMID: 34745259 DOI: 10.1155/2021/3658196] [Reference Citation Analysis]
195 Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona N, Cejalvo JM, González-Barrallo I, Martín-Arana J, Tébar-Martínez R, Viala A, Bruixola G, Hernando C, Blasco I, Papaccio F, Martínez-Ciarpaglini C, Alfaro-Cervelló C, Seda-García E, Blesa S, Chirivella I, Castillo J, Montón-Bueno JV, Roselló S, Huerta M, Pérez-Fidalgo A, Martín-Martorell P, Insa-Mollá A, Fleitas T, Rentero-Garrido P, Zúñiga-Trejos S, Cervantes A, Roda D. Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. Br J Cancer 2021;125:1261-9. [PMID: 34493820 DOI: 10.1038/s41416-021-01502-x] [Reference Citation Analysis]
196 Tung JK, Neishaboori N, Haraldsdottir S, Suarez CJ. An amino-terminal BRAF deletion accounting for acquired resistance to RAF/EGFR inhibition in colorectal cancer. Cold Spring Harb Mol Case Stud 2020;6:a005140. [PMID: 32669268 DOI: 10.1101/mcs.a005140] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
197 Yunoki K, Yano T, Yoshimitsu M, Oshita K, Kubota T, Ishida M, Satoh D, Choda Y, Nakano K, Shirakawa Y, Matsukawa H, Idani H, Shiozaki S, Okajima M. Cutaneous metastasis of cecum cancer with MSI-high and BRAFV600E mutation: a case report. Surg Case Rep 2021;7:185. [PMID: 34406516 DOI: 10.1186/s40792-021-01265-w] [Reference Citation Analysis]
198 Invrea F, Punzi S, Petti C, Minelli R, Peoples MD, Bristow CA, Vurchio V, Corrado A, Bragoni A, Marchiò C, Bertotti A, Trusolino L, Bardelli A, Isella C, Carugo A, Draetta GF, Medico E. Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways. Cancers (Basel) 2021;13:3805. [PMID: 34359705 DOI: 10.3390/cancers13153805] [Reference Citation Analysis]
199 Shuford RA, Cairns AL, Moaven O. Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements Towards Individualizing the Treatment. Cancers (Basel) 2020;12:E3481. [PMID: 33238500 DOI: 10.3390/cancers12113481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
200 Ikoma T, Shimokawa M, Kotaka M, Matsumoto T, Nagai H, Boku S, Shibata N, Yasui H, Satake H. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan. BMC Cancer 2021;21:518. [PMID: 33962575 DOI: 10.1186/s12885-021-08271-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
201 Nagayama S, Low SK, Kiyotani K, Nakamura Y. Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy. Cancers (Basel) 2021;13:4803. [PMID: 34638288 DOI: 10.3390/cancers13194803] [Reference Citation Analysis]
202 Kitagawa Y. Tumor-agnostic precision oncology: striving to prioritize internationalization for the management of cancer patients. Int J Clin Oncol 2020;25:995-6. [PMID: 32367258 DOI: 10.1007/s10147-020-01680-3] [Reference Citation Analysis]
203 González Astorga B, Salvà Ballabrera F, Aranda Aguilar E, Élez Fernández E, García-Alfonso P, González Flores E, Vera García R, Fernández Montes A, López Muñoz AM, Salud Salvia A. Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. Clin Transl Oncol 2021;23:1520-8. [PMID: 33630242 DOI: 10.1007/s12094-021-02568-y] [Reference Citation Analysis]
204 Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, Naing A, Hong DS, Fu S, Piha-Paul SA, Tsimberidou AM, Janku F, Meric-Bernstam F, Kurzrock R, Falchook G. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol 2020;9:7. [PMID: 32337094 DOI: 10.1186/s40164-020-00159-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
205 Pestana RC, Sen S, Hobbs BP, Hong DS. Histology-agnostic drug development - considering issues beyond the tissue. Nat Rev Clin Oncol 2020;17:555-68. [PMID: 32528101 DOI: 10.1038/s41571-020-0384-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
206 Fanelli GN, Dal Pozzo CA, Depetris I, Schirripa M, Brignola S, Biason P, Balistreri M, Dal Santo L, Lonardi S, Munari G, Loupakis F, Fassan M. The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. Cancer Cell Int. 2020;20:30. [PMID: 32015690 DOI: 10.1186/s12935-020-1117-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
207 Voutsadakis IA. Successful treatment of locally advanced urachal adenocarcinoma with peri-operative gemcitabine - cisplatin combination therapy: a case report and perspective on targeted therapies. Cent European J Urol 2020;73:476-81. [PMID: 33552573 DOI: 10.5173/ceju.2020.0176] [Reference Citation Analysis]
208 Randon G, Intini R, Cremolini C, Elez E, Overman MJ, Lee J, Manca P, Bergamo F, Pagani F, Antista M, Angerilli V, Ros Montaña FJ, Lavacchi D, Boccaccino A, Fucà G, Brich S, Cattaneo L, Fassan M, Pietrantonio F, Lonardi S. Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. European Journal of Cancer 2022;161:90-8. [DOI: 10.1016/j.ejca.2021.11.018] [Reference Citation Analysis]
209 Chakrabarti S, Peterson CY, Sriram D, Mahipal A. Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. World J Gastrointest Oncol 2020; 12(8): 808-832 [PMID: 32879661 DOI: 10.4251/wjgo.v12.i8.808] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
210 Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med 2020;383:1207-17. [PMID: 32955176 DOI: 10.1056/NEJMoa1917239] [Cited by in Crossref: 203] [Cited by in F6Publishing: 121] [Article Influence: 101.5] [Reference Citation Analysis]
211 Giuliani J, Mantoan B, Bonetti A. Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer. J Oncol Pharm Pract 2021;:10781552211045006. [PMID: 34581610 DOI: 10.1177/10781552211045006] [Reference Citation Analysis]
212 Dennison L, Mohan AA, Yarchoan M. Tumor and Systemic Immunomodulatory Effects of MEK Inhibition. Curr Oncol Rep 2021;23:23. [PMID: 33547983 DOI: 10.1007/s11912-020-01008-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
213 Takeda H, Sunakawa Y. Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives. Front Oncol 2021;11:602194. [PMID: 33842313 DOI: 10.3389/fonc.2021.602194] [Reference Citation Analysis]
214 Marmorino F, Boccaccino A, Germani MM, Falcone A, Cremolini C. Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. Cancers (Basel). 2020;12. [PMID: 32824490 DOI: 10.3390/cancers12082317] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
215 Uhlitz F, Bischoff P, Peidli S, Sieber A, Trinks A, Lüthen M, Obermayer B, Blanc E, Ruchiy Y, Sell T, Mamlouk S, Arsie R, Wei TT, Klotz-Noack K, Schwarz RF, Sawitzki B, Kamphues C, Beule D, Landthaler M, Sers C, Horst D, Blüthgen N, Morkel M. Mitogen-activated protein kinase activity drives cell trajectories in colorectal cancer. EMBO Mol Med 2021;13:e14123. [PMID: 34409732 DOI: 10.15252/emmm.202114123] [Reference Citation Analysis]
216 Riera P, Rodríguez-Santiago B, Lasa A, Gonzalez-Quereda L, Martín B, Salazar J, Sebio A, Virgili AC, Minguillón J, Camps C, Surrallés J, Páez D. Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients. Cancers (Basel) 2020;12:E2245. [PMID: 32796636 DOI: 10.3390/cancers12082245] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
217 Liu Z, Zhang Y, Dang Q, Wu K, Jiao D, Li Z, Sun Z, Han X. Genomic Alteration Characterization in Colorectal Cancer Identifies a Prognostic and Metastasis Biomarker: FAM83A|IDO1. Front Oncol 2021;11:632430. [PMID: 33959500 DOI: 10.3389/fonc.2021.632430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Imyanitov E, Kuligina E. Molecular testing for colorectal cancer: Clinical applications. World J Gastrointest Oncol 2021; 13(10): 1288-1301 [PMID: 34721767 DOI: 10.4251/wjgo.v13.i10.1288] [Reference Citation Analysis]
219 Koopman M, Pinto C, Bodoky G, Garcia-carbonero R, Marti F, Bachet J. Rationale and design of the PROMETCO study: a real-world, prospective, longitudinal cohort on the continuum of care of metastatic colorectal cancer from a clinical and patient perspective. Future Oncology. [DOI: 10.2217/fon-2021-1333] [Reference Citation Analysis]
220 Gruijs M, Braster R, Overdijk MB, Hellingman T, Verploegen S, Korthouwer R, van der Wilk BJ, Parren PWHI, van der Vliet HJ, Bögels M, van Egmond M. Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer Cells. J Oncol 2022;2022:3577928. [PMID: 35035479 DOI: 10.1155/2022/3577928] [Reference Citation Analysis]
221 Roosan MR, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Chao J, Chen C, Nasser MW, Chirravuri-Venkata R, Jain M, Smith L, Yost SE, Reckamp KL, Pillai R, Arvanitis L, Afkhami M, Wang EW, Chung V, Cristea M, Fakih M, Koczywas M, Massarelli E, Mortimer J, Yuan Y, Batra SK, Pal S, Salgia R. Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. Cancers (Basel) 2021;13:2776. [PMID: 34204917 DOI: 10.3390/cancers13112776] [Reference Citation Analysis]
222 Filip S, Vymetalkova V, Petera J, Vodickova L, Kubecek O, John S, Cecka F, Krupova M, Manethova M, Cervena K, Vodicka P. Distant Metastasis in Colorectal Cancer Patients-Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review. Int J Mol Sci 2020;21:E5255. [PMID: 32722130 DOI: 10.3390/ijms21155255] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
223 Seligson ND, Knepper TC, Ragg S, Walko CM. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine. Clin Pharmacol Ther 2021;109:334-42. [PMID: 32535906 DOI: 10.1002/cpt.1946] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
224 Czauderna C, Luley K, von Bubnoff N, Marquardt JU. Tailored Systemic Therapy for Colorectal Cancer Liver Metastases. Int J Mol Sci 2021;22:11780. [PMID: 34769209 DOI: 10.3390/ijms222111780] [Reference Citation Analysis]
225 Šuštić T, Bosdriesz E, van Wageningen S, Wessels LFA, Bernards R. RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS-mutant colorectal cancer. Transl Oncol 2020;13:201-11. [PMID: 31865182 DOI: 10.1016/j.tranon.2019.10.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
226 Malki A, ElRuz RA, Gupta I, Allouch A, Vranic S, Al Moustafa AE. Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements. Int J Mol Sci 2020;22:E130. [PMID: 33374459 DOI: 10.3390/ijms22010130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
227 Frank MH, Wilson BJ, Gold JS, Frank NY. Clinical Implications of Colorectal Cancer Stem Cells in the Age of Single-Cell Omics and Targeted Therapies. Gastroenterology 2021;160:1947-60. [PMID: 33617889 DOI: 10.1053/j.gastro.2020.12.080] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
228 Middleton G, Yang Y, Campbell CD, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, De Vos F, Van Cutsem E, Millholland JM, Brase JC, Rangwala F, Gasal E, Corcoran RB. BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. Clin Cancer Res 2020;26:2466-76. [PMID: 32047001 DOI: 10.1158/1078-0432.CCR-19-3579] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
229 Liu D. Cancer biomarkers for targeted therapy. Biomark Res 2019;7:25. [PMID: 31807308 DOI: 10.1186/s40364-019-0178-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]